Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: KN052
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT05309512
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
Phase 3
Active, not recruiting
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: placebo
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 408
- Registration Number
- NCT05149326
- Locations
- 🇨🇳
Affiliated Hospital of Jining Medical University, Jining, Shandong, China
🇨🇳The Second Hospital Of Anhui medical University, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Phase 2
Terminated
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT05001724
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT04881929
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
Terminated
- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- Drug: KN026 combined with Palbociclib and Fulvestrant
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 4
- Registration Number
- NCT04778982
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
Phase 1
Terminated
- Conditions
- Advanced HCC
- Interventions
- Drug: KN046 （PD-L1/CTLA4 BsAb）
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT04601610
- Locations
- 🇨🇳
Chinese Pla General Hospital Chinese Pla Medical School, Beijing, Beijing, China
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Phase 2
Completed
- Conditions
- HER2-positive Solid Tumors
- Interventions
- Drug: KN026 combination
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 102
- Registration Number
- NCT04521179
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 482
- Registration Number
- NCT04474119
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 95
- Registration Number
- NCT04469725
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: KN026 monotherapyDrug: KN026 combinationDrug: Concurrent chemotherapy and KN026
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 68
- Registration Number
- NCT04165993
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
© Copyright 2025. All Rights Reserved by MedPath